Express News | Axsome Therapeutics Inc : UBS Cuts Target Price to $143 From $149
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Investors in Axsome Therapeutics (NASDAQ:AXSM) Have Seen Strong Returns of 235% Over the Past Three Years
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $190
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Axsome Therapeutics (AXSM) and Greenwich LifeSciences (GLSI)
Positive Outlook on Axsome Therapeutics' AXS-12 for Narcolepsy Treatment Amid Promising Phase III Results
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
New Analyst Forecast: $AXSM Given 'Buy' Rating
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Jefferies Initiates Coverage On Axsome Therapeutics With Buy Rating, Announces Price Target of $200
Jefferies Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $200
Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $200
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $190
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
Axsome Therapeutics Price Target Maintained With a $200.00/Share by HC Wainwright & Co.
Axsome Therapeutics Analyst Ratings
RBC Trims Price Target on Axsome Therapeutics to $190 From $192, Keeps Outperform Rating
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $153 to $216